{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:04:45Z","timestamp":1789941885802,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.bone.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:32:01Z","timestamp":1381365121000},"page":"103-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients"],"prefix":"10.1016","volume":"58","author":[{"given":"G\u00e9raldine","family":"Lescaille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie E.","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Baaroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Ostertag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jos\u00e9","family":"Javelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Tol\u00e9do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Goudot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Az\u00e9rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Berdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Ruhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Descroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.10.002_bb0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","article-title":"Epidemiology and pathogenesis of osteonecrosis of the jaw","volume":"8","author":"Reid","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2013.10.002_bb0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.002_bb0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.002_bb0020","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S1470-2045(08)70305-X","article-title":"Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw","volume":"9","author":"Edwards","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0025","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","article-title":"Osteonecrosis of the jaw: who gets it, and why?","volume":"44","author":"Reid","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.002_bb0035","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0040","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0045","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Di\u015fel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.joms.2011.02.104","article-title":"Osteonecrosis after administration of intravitreous bevacizumab","volume":"70","author":"Hopp","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.002_bb0055","first-page":"2009","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","author":"Pakosch","year":"2012","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.002_bb0060","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.4317\/medoral.16.e137","article-title":"Maxillary osteonecrosis associated to antiangiogenic drugs","volume":"16","author":"Salort-Llorca","year":"2011","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.bone.2013.10.002_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bone.2013.10.002_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bone.2013.10.002_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.bone.2013.10.002_bb0080","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bone.2013.10.002_bb0085","first-page":"c85","article-title":"Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J Can Dent Assoc"},{"key":"10.1016\/j.bone.2013.10.002_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.surge.2011.09.002","article-title":"Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review","volume":"10","author":"McLeod","year":"2012","journal-title":"Surgeon"},{"key":"10.1016\/j.bone.2013.10.002_bb0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.002_bb0100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.120810","article-title":"Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?","volume":"40","author":"Lescaille","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bone.2013.10.002_bb0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws \u2014 a review","volume":"48","author":"K\u00fchl","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0110","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws \u2014 2009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.002_bb0115","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","article-title":"Bisphosphonates and time to osteonecrosis development","volume":"14","author":"Palaska","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2013.10.002_bb0120","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0125","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1200\/JCO.2011.35.1551","article-title":"Osteonecrosis of the jaw after zoledronic acid and denosumab treatment","volume":"29","author":"Fusco","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0130","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bone.2013.10.002_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.2010.05768.x","article-title":"Bisphosphonate-related osteonecrosis of the jaw: an overview","volume":"1218","author":"Ruggiero","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2013.10.002_bb0145","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bone.2013.10.002_bb0150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.10.002_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jnci\/djq516","article-title":"Osteonecrosis of the jaw and the role of macrophages","volume":"103","author":"Pazianas","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bone.2013.10.002_bb0160","first-page":"1","article-title":"Can peripheral blood \u03b3\u03b4 T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug-effects of aminobisphosphonate therapy","author":"Kalyan","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.10.002_bb0165","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.oooo.2012.08.457","article-title":"Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies","volume":"114","author":"Cho","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bone.2013.10.002_bb0170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tripleo.2007.08.040","article-title":"Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology","volume":"105","author":"Bedogni","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.bone.2013.10.002_bb0175","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.bone.2013.10.002_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T11:30:18Z","timestamp":1564486218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213003797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"alternative-id":["S8756328213003797"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.002","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}